Upstream Processing in Biopharmaceuticals - Increasing use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market - GBI Research Reports

Upstream Processing in Biopharmaceuticals - Increasing use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market

Upstream Processing in Biopharmaceuticals - Increasing use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market - GBI Research Reports
Upstream Processing in Biopharmaceuticals - Increasing use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market
Published Mar 25, 2011
109 pages — Published Mar 25, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research's report, Upstream Processing in Biopharmaceuticals - Increasing Use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market, provides the key to market data on overall upstream process, Contract Manufacturing Organization (CMO) market for upstream processing, and the cell culture and reagent market. Market. The report also analyzes the strengths, weaknesses, opportunities, and threats for the key players in the CMO and cell culture and regent market. The report also discusses the key market drivers and restraints for the upstream processing, outsourcing to CMO and cell culture and reagent market. The report is based on proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts to provide a comprehensive view of the upstream processing in biopharmaceuticals.

Scope

The scope of this report includes -
- Key emerging technologies in upstream processing for the manufacturers of Biopharmaceuticals in the pharmaceuticals industry
- Market revenues and forecasts for upstream Processing of Biopharmaceuticals in the CMO market from 2009 to 2016.
- Key drivers, restraints challenges and trends in upstream processing.
- Technology landscape along with their application in upstream bioprocess that shape the bio manufacturing industry
- Analysis of competitive assessment of key CMO and cell culture and reagent players.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Formulate strategies to increase your companys growth by understanding the new growth opportunities, market size and growth prospectus in the upstream market.
- Work around the technology hurdles by identifying the key trends shaping and driving the market for upstream process.
- Differentiate yourself from competitors and develop new solutions for the bio pharmaceutical manufacturing industry by understanding the existing competitive landscape and how it is evolving to meet the increasing demands.
- Draft efficient strategies by understanding best practices, identifying key players in the CMO market and cell culture and regent market.

  
Source:
Document ID
GBIHC065MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents37
  List of Tables71
  List of Figures82
Upstream Processing in Biopharmaceuticals Introduction101
  GBI Research Report Guidance101
Upstream Processing in Biopharmaceuticals -Biopharmaceuticals Overview119
  Important Classes of Biopharmaceuticals111
    Monoclonal Antibodies (mAb)121
    Vaccines121
    Hormones121
    Enzymes121
    Interferon121
    Clotting Factors121
    Therapeutic Protein131
  Biopharmaceutical Manufacturing Process Overview141
    Overview of Microbial Fermentation151
    Overview of Mammalian Cell Culture Systems151
    Cell Banking and Seed Culture151
      Research Cell Banks161
      Master Cell Banks161
      Working Cell Banks (WCB)161
    Overview of Upstream Process161
    Harvest171
    Downstream Process (DSP)171
      Initial Clarification181
      Initial Capture181
      Intermediate Purification181
      Final Polishing191
    Formulation191
    Comparison of Upstream Processing and Downstream Processing191
Upstream Processing in Biopharmaceuticals Upstream Process In Detail2010
  Introduction201
  Bioreactors and Cells212
  In Process Control231
    pH231
    Temperature241
      Effect of High Temperature241
      Effect of Low Temperature241
    Holding and Storage Time241
    Shear Forces241
    Key Points to be remembered while starting Up Upstream Processes241
    Major Issues during Upstream Processing251
  Scale Up251
    The Upstream Output can be increased261
      Use of Alternative Ways to Improve Protein Expression System261
      Disposable Technologies to Reduce the Process Time271
    Upstream Bioprocessing281
    Some Key Points While Starting Up Upstream Processes281
      Case Study: Use of Parallel Vessel Approach to Increase Productivity281
    Emerging Production Systems in Upstream Bioprocess291
      Efficient Filtration Mechanism291
      Contamination Detection Techniques291
    Conclusion291
Upstream Processing in Biopharmaceuticals Market Characterization3025
  Culture Media Overview301
    Cell Culture301
      Lysogeny Broth (LB)301
      Serum Free Media (SFM)301
      Protein-Free Media301
      Specialty Media311
  Key Biologic Reagents311
    Amino Acids311
    Growth Factors311
    Albumin311
    Transferrin311
  Culture Media/Reagent Suppliers321
  Culture Media/Reagent Market Size331
    Market Drivers341
      Huge Demand of Biologics and Regulatory Acceptance to Biosimilars will Drive Cell Culture Market341
      Development of Stem Cell Culturing Protocols and Technologies will Boost Cell Culture Market341
      Advancement in Biomedical Research351
      Vaccines Production by Using Cell Culture will be an Important Driver of the Market in the near Future351
    Market Restraints351
      Use of Transgenic Plants and Animals for the Biopharmaceutical Production is the Only Obstacle to the Cell Culture Market351
  Bioreactor351
    Selection of Bioreactors351
    Batch Bioreactor361
      Characteristics361
      Common Applications361
    Continuous Bioreactor371
      Key Features371
      Characteristics371
      Common Applications381
    Submerged Bioreactors Stirred Tank381
    Airlift Bioreactor381
      Characteristics381
      Summary381
  Upstream Process and CMO391
    Why CMO?391
    Build Vs. Buy Decision391
      Financial Considerations391
      Feasibility401
      Risk Management and Assessment401
      Strategic Fit401
      Conclusion401
    Selection of CMOs411
      Manufacturing Specialty411
      Scale of Manufacturing421
      Maintenance of Standard421
      Industry Reputation421
    CMO- Upstream Market Size431
    Drivers for Outsourcing441
      Manufacturing Cost Saving and Convenience in Various Biopharmaceutical Processes offered by CMO Encourages Outsourcing452
      Biotechnology Companies are Outsourcing to Reduce Operational Risk and Entry into the Market471
      Regulatory Changes471
      Growth in Biopharmaceuticals Market: Rise in Demand for Biologics Continues to Drive the Industry to Contract Manufacturing Services471
    Restraints to Outsourcing481
      Complex Cost Structures in Outsourcing481
      Time and Cost Associated with the Process of Outsourcing481
      Harmonization between In-house and Outsourced Process Makes Manufacturing More Difficult481
  Upstream Process Market Size491
  Upstream Process Trends501
    Inclination towards the Transgenic Plant/ Animals502
    R&D and Technology Based Advancements in Upstream Process521
    Focus on Single Use Technology521
  Upstream Process Drivers531
    Advances in Media and Cell-Line Development will Improve Overall Upstream Process Market531
    Innovations in Transgenic Production Systems will Drive Upstream Process Market in Future541
    Emergence of Newer Technologies Will Improve the Upstream Processing541
  Upstream Process Restraints541
    R&D Focus has Shifted to Downstream Process541
    High Cost and Time Spent in Upstream Process Affecting Productivity541
Upstream Processing in Biopharmaceuticals Competitive Landscape5518
  Key Players in the Culture Media and Reagents Market551
    Life Technologies551
      Company Overview551
      SWOT Analysis561
    Sigma Aldrich Corporation571
      Company Overview571
      SWOT Analysis581
    Millipore Corporation (a Merck KGaA company)591
      Company Overview591
      SWOT Analysis601
    Thermo Fisher Scientific611
      Company Overview611
      SWOT Analysis621
  Key CMO Players631
    Lonza Group Ltd (Lonza)631
      Company Overview631
      SWOT Analysis641
    Boehringer Ingelheim GmbH (Boehringer)651
      Company Overview651
      SWOT Analysis661
    Avecia Biotechnology671
      Company Overview671
      SWOT Analysis681
    Diosynth Biotechnology691
      Company Overview691
      SWOT Analysis701
    Sandoz GmbH (Sandoz)711
      Company Overview711
      SWOT Analysis721
Upstream Processing in Biopharmaceuticals Technology Landscape7315
  Transgenic Animals (A Live Bioreactor)731
    Transgenic Chickens741
    Proteins from Herd741
      Challenges741
  Transgenic Plants751
    Innovative Technologies761
      Lemna761
      Focus on Production of Oral Vaccines Edible Transgenic Plant771
      Plant Chloroplast Transformation781
    Challenges781
      Technical Challenges791
      Regulatory Challenges791
      Economic Challenges791
      Safety Concerns: Questions are being raised About Safety and Risk Associated with Transgenic Plants791
    Cell Culture801
      Innovative Technologies802
      Challenges821
  Single Use Disposable Bioreactors831
    Wave Reactor: (GE Healthcare) The maximum working volume for the Wave is 500 L831
    Single-Use Bioreactor (HyClone) available in sizes up to 1,000 L841
    Single-Use XDR Bioreactor (Xcellerex)841
    Hollow-Fiber Cartridges (Biovest)841
    Single-Use Mixing Systems841
    Some Recent Products Developed by Major Firms841
      Sartorius Stedim Biotech841
      Allegro841
      Wave Biotech841
      Millipore851
    Challenges851
      Low Rate of Implementation851
      Technology Improvement851
      Compatibility Challenge861
      Scale Up Challenge861
      Safety Issue861
  Use of Information Technology to Increase Productivity862
Upstream Processing in Biopharmaceuticals Guidelines, Regulatory Landscape8812
  Quality by Design (QbD)882
  Process Analytical Technology (PAT)901
    Importance of PAT911
    Factors Limiting Implementation of PAT911
      Real and Perceived Technological Barriers911
      Lack of Economic Incentive911
    A summary of PAT benefits is as follows:911
  ICH Guidelines921
    Q5A (R1): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin921
    Q5B: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products921
      Expression Construct and Cell Clone Used to Develop the Master Cell Bank (MCB)931
      Cell Bank System931
      Limit for In Vitro Cell Age for Production931
    Q5C: Quality of Biotechnological Products Stability Testing of Biological Products931
    Q5D: Derivation and Characterizations of Cell Substrates Used for Production of Biotechnological/Biological Products931
    Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process941
  The US Regulatory Landscape941
    PHS Act941
  Europe Regulatory Landscape951
    EMEA Guidelines951
      Quality Management951
      Production Activities961
      Buildings and Facilities961
      Process Equipment971
      Materials Management971
      Packaging and labeling971
    Key Changes in EMEA Guidelines981
    Types of Guidelines within the Biologics Legislative981
      Good Manufacturing Practice (GMP) Guidelines981
      Maximum Residue Limits Guidelines981
      Good Clinical Practice (GCP) and Conduct of Clinical Trial Guidelines981
      Good Distribution Practice (GDP) Guidelines981
  Japan981
    Health Policy Bureau981
    Office 1991
    Office 2991
    Review and Guidelines991
Upstream Processing in Biopharmaceuticals Strategic Consolidations1005
  Reasons for Strategic Consolidations in Biologics Manufacturing1001
    Uninterrupted Supply to Meet the Demand1001
    Overall Cost Reduction1001
    Global Expansion to Stay Ahead in Competition1001
    High Regulation Requirement1001
    Acquiring Technical Expertise1001
    Time Pressure and Synergy Innovation1011
  Potential Problems in Strategic Consolidations1011
    Incorrect Valuation1011
    Capital Problem1011
    Compliance Difficulty1011
  Important Alliances in Biologics Manufacturing1011
    Lonza in an Agreement with Odyssey Thera, Inc.1011
    DSM Biologics (DSM) and Crucell NV Enter into an Agreement with Bioceros BV1011
    Cobra Biomanufacturing Plc (Cobra)1021
    Angel Biotechnology Holdings Plc1021
    DSM Biologics Has Entered into an Agreement with Australian Governments to Build and Operate a Biopharmaceutical Manufacturing Facility in Brisbane1021
    Lonza Enter into Licensing Agreement with Crucell1021
    Gamida Cell Enters into Licensing Agreement with Amgen1021
    Life Technologies Enters into Licensing Agreement with Indian Immunological1031
  Recent M&A Deals in Biologics Manufacturing1031
    Genmab Acquiring Manufacturing Facility Currently Owned By PDL Biopharma1031
    BAYER Schering Pharma AG, Germany acquires a biologics manufacturing facility in from Novartis1031

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Upstream Processing in Biopharmaceuticals - Increasing use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market" Mar 25, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Upstream-Processing-in-Biopharmaceuticals-Increasing-use-of-Low-Cost-Disposable-Bioreactors-to-Drive-the-Upstream-Bioprocessing-Market-2115-185>
  
APA:
GBI Research Reports. (2011). Upstream Processing in Biopharmaceuticals - Increasing use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market Mar 25, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Upstream-Processing-in-Biopharmaceuticals-Increasing-use-of-Low-Cost-Disposable-Bioreactors-to-Drive-the-Upstream-Bioprocessing-Market-2115-185>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.